some plans include them for patients with obesity or related conditions, while others may not
In one study, microdosing GLP-1s supported moderate weight loss of up to 10 pounds over 40 weeks in participants. MICRODOSING GLP-1 BENEFITS Do More, Age Less Modulated inflammatory pathways in clinical trials. Studies found a reduced risk of cognitive decline Supported cardiovascular health in clinical trials Improved mitochondrial function and oxidative stress in clinical trials Low doses reduced side effects in clinical trials Supported moderate weight loss of up to 10 pounds over 40 weeks in one study *See studies cited below
Dr Natasha Yates, a GP and PhD candidate at Bond University, cautioned that Mounjaro was one tool in a toolkit that doctors have to help overweight patients and not a cure for obesity
doi:10.1155/2012/324832 Ma WH, Li M, Ma HF, et al
* Regular body composition analyses to ensure fat lossnot muscle loss
A budget-conscious self-pay patient has a different answer again